MIRUM
PharmaMIRUM is a pharmaceutical company focused on Gastroenterology, Infectious Disease. Key products include CHOLBAM.
FDA Novel Drug Designations
(2021)See 1 novel approval →
MIRUM at a Glance
- Growing R&D activity with 7 trials in last 2 years
- Fast trial execution (35 months median completion)
MIRUM's Key Drugs
MIRUM's core commercial portfolio centers on CHOLBAM, LIVMARLI, CTEXLI, spanning Gastroenterology and Infectious Disease — its most strategically important drugs approved in the last 15 years.
MIRUM News
All MIRUM news →MIRUM's Recent FDA Approvals
MIRUM secured 3 new FDA approvals for novel drugs (NDA/BLA) in the last two years.
MIRUM's Therapeutic Areas
MIRUM's approved drugs and pipeline span 2 therapeutic areas, led by Gastroenterology and Infectious Disease, across 0 biologic and 4 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.
MIRUM's Top Competitors
MIRUM's closest competitors by therapeutic-area and drug-target overlap include Johnson & Johnson, Bristol-Myers Squibb, and APOTHECON. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
MIRUM Pipeline Snapshot
MIRUM has 15 active clinical programs from ClinicalTrials.gov — 5 Phase 3, 7 Phase 2 and 3 Phase 1.
Phase 3 Readout Calendar Pro
3 Phase 3 trials with confidence-graded primary completion dates.
Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • CHOLBAM leads revenue
- • 4 key drugs tracked
Trial Catalysts
- • Gastroenterology pipeline focus
- • 3 Phase 3 readouts tracked
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Execution Intelligence
- • Phase 3: 5/9 completed
- • Speed: 35 months avg
Revenue forecasts • Trial milestones • Patent risk modeling
How We Calculate These Metrics
Execution Quality Score
Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.
What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Excellent (80%+): Top-tier execution, most trials reach planned endpoints
- Good (60-79%): Strong execution with occasional early terminations
- Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
- Needs Improvement (under 40%): High termination rates, execution challenges